Raily Aesthetic Medicine International Holdings Limited logo

Raily Aesthetic Medicine International Holdings Limited

2135.HK

HKSEHealthcareMedical - Care Facilities

Latest quote

HK$0.123

+HK$0.007 · +6.03%

Aug 21, 11:37 AM HKTData delayed

2135.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Jianliang Song
Listed since
Dec 28, 2020
Employees
264

Market position

Day range

Current HK$0.123

52-week range

Current HK$0.123

Open
HK$0.119
Previous close
HK$0.116
Volume
10K
0.11× average
Average volume
92.45K
Average daily volume
Market cap
68.52M HKD
Beta
0.39
Market reference 1
50-day average
HK$0.1069
+15.06% above average
200-day average
HK$0.1354
-9.14% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
76.42M CNY
P/E (TTM)
34.01×
P/B (TTM)
0.54×
P/S (TTM)
0.31×
EV / EBITDA
2.83×
Earnings yield
2.43%
Free cash flow yield
42.69%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
40.98%
Operating margin
2.62%
Net margin
0.91%
Return on equity
1.69%
Return on assets
0.77%
Return on invested capital
-688.19%

Financial health

Debt / equity
0.55×
Current ratio
0.77×

Earnings

Latest EPS result
-0.01

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.04-0.02-0.09-0.15Q4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24Q4 '24Q2 '25
Q4 2021, reported Dec 31, 2021: actual -0.031, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 30, 2022: actual 0.004, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 31, 2022: actual -0.041, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual -0.005, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Dec 31, 2023: actual -0.08, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 28, 2024: actual -0.003, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Dec 31, 2024: actual -0.11, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 27, 2025: actual -0.015, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates131.2M112.02M92.83M73.65MQ4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24Q4 '24Q2 '25
Q4 2021, reported Dec 31, 2021: actual 117.14M HKD, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 30, 2022: actual 113.88M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 31, 2022: actual 78.69M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual 110.26M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Dec 31, 2023: actual 101.61M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 28, 2024: actual 126.16M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Dec 31, 2024: actual 87.09M HKD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 27, 2025: actual 92.56M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Mar 19, 2024

1:5

Continue in GoAI

Research 2135.HK

research.disclaimer